The Critical Role of In Vivo Drug Efficacy Studies in Drug Development

In vitro assays provide essential mechanistic insights, but in vivo drug efficacy studies remain the indispensable bridge between cell-based discovery and clinical trials. Animal models recapitulate the complexity of whole-organism physiology — including systemic pharmacokinetics, immune interactions, tumor microenvironments, and multi-organ drug metabolism — that no cell culture system can fully replicate.

Rigorous in vivo efficacy evaluation enables drug developers to:

• Validate therapeutic hypotheses established from in vitro data within a physiologically relevant context
• Characterize pharmacokinetic-pharmacodynamic (PK/PD) relationships to understand exposure-response dynamics
• Evaluate off-target toxicity and therapeutic index in living organisms before committing to IND-enabling studies
• Assess drug efficacy in disease-relevant microenvironments, including tumor-stroma interactions, immune cell infiltration, and organ-specific pathology
• Generate translational biomarker data that informs clinical trial design, including dose selection, patient stratification, and pharmacodynamic endpoints

At Jennio Biotech, our in vivo pharmacology platform spans seven major disease categories, supported by a team of experienced in vivo scientists, well-equipped animal facilities, and a commitment to 3R principles (Replacement, Reduction, Refinement). We work closely with sponsors to design studies that balance scientific rigor with ethical responsibility and regulatory expectations.

Our In Vivo Efficacy Research Platform: Seven Disease Model Categories

Jennio Biotech offers a comprehensive portfolio of in vivo disease models covering the most clinically and commercially significant therapeutic areas. Each model category is supported by validated protocols, experienced study directors, and standardized endpoints to ensure reproducible, regulatory-quality data.

Explore Our In Vivo Disease Model Services

Click on each service below to learn more about our model portfolio and study capabilities.

Tumor & Tumor Immunology Models

Oncology remains the largest segment of our in vivo services. We offer a tiered model system that ranges from rapid screening (CDX) to clinically predictive platforms (PDX, orthotopic, humanized models).

• Cell-Derived Xenograft (CDX) Models — subcutaneous implantation of human tumor cell lines into immunodeficient mice for fast, reproducible efficacy screening and dose-range finding
• Patient-Derived Xenograft (PDX) Models — implantation of fresh patient tumor tissue that preserves tumor heterogeneity, stromal architecture, and clinical drug response patterns for predictive preclinical testing
• Orthotopic Tumor Models — implantation of tumor cells into the anatomically relevant organ (lung, liver, breast, brain) to study tumor progression, metastasis, and organ-specific drug response in a physiologically authentic microenvironment
• Humanized Target Gene Tumor Vaccine Models — genetically engineered models designed for evaluating cancer vaccine candidates and immunotherapies targeting human-specific antigens

Our oncology team supports combination therapy studies (chemo + immunotherapy, targeted + antibody), biomarker analysis (IHC, flow cytometry, ELISA), and PK/PD correlation studies. Explore Oncology Models →

Inflammatory & Autoimmune Disease Models

Chronic inflammatory and autoimmune diseases represent a rapidly growing therapeutic area. Our platform models the key pathological features of these conditions to evaluate anti-inflammatory, immunosuppressive, and biologics candidates.

• Rheumatoid Arthritis Models — collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) in rats/mice, with standardized scoring for joint swelling, histopathology, and inflammatory cytokine profiling
• Inflammatory Bowel Disease (IBD) Models — TNBS-induced and DSS-induced colitis models for evaluating anti-TNF, anti-IL-23, and JAK inhibitor candidates
• Psoriasis Models — imiquimod (IMQ)-induced psoriasis-like skin inflammation model with PASI-like scoring and skin histopathology
• Multiple Sclerosis (EAE) Models — experimental autoimmune encephalomyelitis for neuroinflammation and demyelination drug evaluation

We also support models for systemic lupus erythematosus (SLE), gout, and other autoimmune conditions. Endpoints include clinical scoring, histopathology, cytokine multiplex assays, and flow cytometric immune phenotyping. Explore Immunology Models →

Anti-Infective Drug Evaluation Models

The emergence of drug-resistant pathogens and the need for novel antiviral and antibacterial therapies make in vivo infection models increasingly critical. Jennio Biotech offers validated models for evaluating both antiviral and antibacterial drug candidates.

• Hepatitis B Virus (HBV) Model — a well-characterized in vivo platform using HBV-transgenic or HBV-infected mice for evaluating novel HBV entry inhibitors, capsid assembly modulators, siRNA therapeutics, and immunotherapeutic approaches. Key readouts include serum HBV DNA, HBsAg, HBeAg, intrahepatic cccDNA levels, and histopathological assessment of liver tissue
• Bacterial Infection Models — systemic and localized infection models (sepsis, pneumonia, urinary tract infection) for evaluating antibiotic efficacy, pharmacodynamics, and resistance development
• Viral Infection Models — emerging virus challenge models for antiviral drug screening and host-directed therapy evaluation

Our infectious disease team maintains BSL-2/BSL-3 compliant facilities and collaborates with academic virology groups to ensure model relevance to clinical isolates and emerging variants. Explore Anti-Infective Models →

Metabolic Disease Models

Metabolic diseases including diabetes, fatty liver disease, and obesity represent one of the fastest-growing pharmaceutical markets globally. Our platform provides validated models for evaluating metabolic modulators, GLP-1 analogs, SGLT2 inhibitors, FGF21 analogs, and novel therapeutic mechanisms.

• Type 2 Diabetes Models — high-fat diet (HFD) + STZ-induced diabetic mice, db/db mice, and KK-Ay mice with comprehensive metabolic phenotyping including fasting blood glucose, OGTT, ITT, HbA1c, insulin levels, and lipid profiling
• NAFLD/NASH Models — methionine-choline deficient (MCD) diet, HFD + CCl4, and STAM models for evaluating anti-fibrotic, anti-steatotic, and anti-inflammatory drug candidates. Endpoints include liver histology (NAS scoring), serum ALT/AST, hepatic triglycerides, hydroxyproline content, and fibrosis gene expression profiling
• Obesity Models — diet-induced obesity (DIO) in C57BL/6J mice and genetic models (ob/ob) for anti-obesity drug evaluation including body weight, food intake, body composition (DEXA), energy expenditure (metabolic cages), and adipose tissue histopathology

Explore Metabolic Models →

Chronic Disease Models

Chronic diseases with progressive pathology — particularly pulmonary conditions — require longitudinal in vivo models that recapitulate disease onset, progression, and response to therapy over extended time courses.

• Pulmonary Fibrosis Models — bleomycin-induced lung fibrosis in mice and rats, with sequential evaluation of lung function (plethysmography), histopathology (Masson’s trichrome, Ashcroft scoring), hydroxyproline content, and fibrosis-related gene and protein expression
• Acute/Chronic Lung Injury Models — LPS-induced and cigarette smoke-induced models for evaluating anti-inflammatory and anti-fibrotic drug candidates, with BALF analysis, cytokine profiling, and lung histopathology
• COPD Models — chronic cigarette smoke exposure or elastase-induced emphysema models with pulmonary function testing and inflammatory cell infiltration analysis

These models are particularly relevant for programs targeting novel pathways such as TGF-β signaling, lysophosphatidic acid (LPA) pathways, and integrin-based anti-fibrotic approaches. Explore Chronic Disease Models →

Cardiovascular Disease Models

Cardiovascular disease remains the leading cause of death worldwide. Our in vivo cardiovascular models support the evaluation of anti-atherosclerotic, antihypertensive, cardioprotective, and lipid-modulating therapies.

• Atherosclerosis Models — ApoE-/- and LDLR-/- mice fed high-fat or Western diet, with en face aorta Oil Red O staining, aortic root histopathology, serum lipid profiling, and inflammatory cytokine analysis
• Myocardial Infarction Models — LAD coronary artery ligation in rats/mice for evaluating cardioprotective drugs, with echocardiographic assessment of cardiac function, infarct size measurement (TTC staining), and cardiac remodeling histopathology
• Hypertension Models — spontaneously hypertensive rats (SHR) and Ang II-induced hypertensive mice for evaluating antihypertensive drug candidates with blood pressure monitoring (tail-cuff or telemetry)

Endpoints include echocardiography, ECG, blood pressure telemetry, serum biomarkers (troponin, BNP, CK-MB), and comprehensive cardiac histopathology. Explore Cardiovascular Models →

Orthopedic Disease Models

Musculoskeletal diseases including osteoarthritis, osteoporosis, and impaired bone healing represent a significant unmet medical need, particularly in aging populations. Jennio Biotech provides validated orthopedic models for evaluating disease-modifying osteoarthritis drugs (DMOADs), bone anabolic agents, and novel regenerative therapies.

• Osteoarthritis Models — anterior cruciate ligament transection (ACLT), destabilization of the medial meniscus (DMM), and monosodium iodoacetate (MIA)-induced models with OARSI histopathology scoring, micro-CT analysis of subchondral bone, and inflammatory cytokine measurement in synovial fluid
• Osteoporosis Models — ovariectomy (OVX)-induced osteoporosis in rats and mice for evaluating anti-resorptive (bisphosphonates, RANKL inhibitors) and anabolic (PTH analogs, sclerostin antibodies) therapies with DXA bone mineral density, micro-CT trabecular architecture, and biomechanical testing
• Bone Fracture Healing Models — stabilized femoral fracture and calvarial defect models for evaluating bone regeneration and fracture healing acceleration

Explore Orthopedic Models →

Why Partner with Jennio Biotech for In Vivo Efficacy Studies

1. Breadth of Disease Model Coverage

With seven disease categories under one platform, sponsors can consolidate multiple preclinical programs with a single CRO partner, reducing vendor management complexity and ensuring data consistency across therapeutic areas.

2. Experienced In Vivo Scientific Team

Our study directors have collectively managed hundreds of in vivo efficacy studies across oncology, immunology, metabolic diseases, and beyond. We bring hands-on expertise in animal surgery, model validation, dose optimization, and regulatory-compliant study execution.

3. Integrated Preclinical Capabilities

Jennio Biotech’s in vivo services are seamlessly integrated with our in vitro drug efficacy research platform, non-GLP pharmacology and toxicology services, and specialized drug efficacy research platforms. This integration enables translational research workflows that connect cellular mechanisms to whole-organism efficacy — a decisive advantage for IND-enabling programs.

4. Flexible Study Design & Customization

Every sponsor’s program is unique. We don’t force-fit projects into standard protocols — instead, we co-design customized study plans that align with your specific scientific questions, development timeline, and regulatory strategy. From pilot studies to GLP-compliant pivotal studies, we adapt to your needs.

5. Commitment to Animal Welfare & Data Quality

Our animal facilities operate under strict ethical oversight with IACUC-approved protocols. We implement 3R principles throughout the study lifecycle — optimizing group sizes through power analysis, refining procedures to minimize distress, and employing humane endpoints. Well-cared-for animals produce better, more reproducible science.

Typical In Vivo Efficacy Study Workflow

Our structured study process ensures scientific rigor, regulatory compliance, and clear communication at every stage:

Frequently Asked Questions

What species of animals do you use for in vivo efficacy studies?
Our in vivo studies primarily utilize mice and rats, which are the most widely accepted species for preclinical efficacy evaluation due to their well-characterized genetics, availability of disease models, and cost-effectiveness. For specific programs, we can also accommodate studies using hamsters, guinea pigs, or rabbits. We work with both immunodeficient strains (for human xenograft studies) and immunocompetent strains (for immunology, infectious disease, and syngeneic tumor models).

Can you support GLP-compliant in vivo studies?
Our in vivo studies are conducted under standardized SOPs with comprehensive documentation suitable for IND-enabling submissions. For programs requiring formal GLP compliance, we coordinate with our GLP-certified partner facilities to deliver fully GLP-compliant pivotal toxicology and safety pharmacology studies. Please contact us to discuss your specific regulatory requirements.

What is the typical turnaround time for an in vivo efficacy study?
Turnaround time varies by model type and study complexity. A standard 4-week CDX efficacy study (including model establishment, treatment, and reporting) typically takes 6–8 weeks total. PDX studies may require 12–16 weeks due to engraftment time. Chronic disease models (fibrosis, metabolic disease) with longitudinal dosing may require 8–14 weeks. We provide detailed timeline estimates during proposal development.

Do you support combination therapy studies?
Yes. Combination therapy evaluation is one of our most frequently requested study designs, particularly in oncology (chemo + immunotherapy, targeted therapy + anti-angiogenic) and infectious diseases (combination antiviral regimens). We design multi-arm studies with appropriate statistical comparisons (monotherapy vs. combination vs. vehicle) and can evaluate synergy using Bliss independence or Loewe additivity models.

Can we schedule a site visit or remote meeting before starting a project?
Absolutely. We welcome sponsor site visits to our animal facility in Guangzhou and can arrange remote video conferences at your convenience. During these meetings, our study directors will walk you through our facility capabilities, model validation data, and proposed experimental design. Please contact us to schedule a visit or meeting.

Ready to advance your preclinical program? Contact our in vivo pharmacology team today to discuss your disease model needs. We’ll respond within 24 hours with a tailored study proposal.
Email: 3691125803@qq.com | Phone/WeChat: +86 18802035152